Hair loss with GLP-1 drugs is rare, but real, studies find By Nancy Lapid July 22 (Reuters) - The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest
Taking semaglutide with a light meal 30 minutes before eating, rather than at random times, optimizes peak GLP-1 receptor occupancy during your eating window
Important Safety and Legal Information Henry Meds is a telehealth platform that connects patients with licensed healthcare providers for online consultations
Bjorklund says she used Ozempic for more than a year, stopping around July 2023
This policy change affects Medicare beneficiaries who rely on these drugs primarily for obesity treatment rather than for an approved condition like type 2 diabetes
While these drugs share some similarities, they also have some differences